A carregar...

Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer

To discuss the mechanism and clinical application of EGFR-TKI and ALK/ROS1 inhibitors in non-small cell lung cancer (NSCLC), we reviewed recent available data mainly from PubMed. We found that chemotherapy, progression-free survival (PFS), objective response rate (ORR), and quality of life of patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Clin Exp Med
Main Authors: Ge, Liangqing, Shi, Ruizheng
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4565207/
https://ncbi.nlm.nih.gov/pubmed/26379824
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!